ExpreS2ion Biotech Holding AB (publ) Return on Equity

ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST) currently reports a ROE of -85.96%. That is below the Healthcare sector average of -75.59%. Use the charts on this page to explore ExpreS2ion Biotech Holding AB (publ)'s ROE history and peer comparisons.

ExpreS2ion Biotech Holding AB (publ)'s ROE of -85.96% is lower than the Healthcare sector average of -75.59%. That is roughly 13.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but ExpreS2ion Biotech Holding AB (publ)'s current -85.96% should be judged against Healthcare norms (sector average: -75.59%) and against EXPRS2.ST's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -85.96%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.59%. From there, open related valuation or income-statement pages for ExpreS2ion Biotech Holding AB (publ), and consider following EXPRS2.ST for alerts when major investors trade the stock.

ExpreS2ion Biotech Holding AB (publ) is classified in the Healthcare sector. On ROE, it currently shows -85.96% versus a sector average near -75.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EXPRS2.ST with unrelated industries.